Nimbus hires Loh from Kymera to lead biology team

Business documents being signed
Christine Loh leaves Kymera Therapeutics two months after it changed CEO. (Yok46233042/iStock/Getty Images Plus)

Nimbus Therapeutics has hired Christine Loh to lead its biology team. Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

Kymera hired Loh as vice president of biology in 2017 and moved her to the VP of translational medicine post earlier this year. Those positions gave Loh a leading role in Kymera’s biomarker strategy, patient selection and efforts to build up resources to take drug candidates into the clinic. Kymera is due to take a IRAK4 protein degrader into the clinic next year. 

Prior to joining Kymera, Loh, who has a Ph.D. in immunology, spent spells at Biogen, Bioverativ, Pfizer and GlaxoSmithKline’s Sirtris. Loh worked in areas including target research and immunology during those spells.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

That background landed Loh the position of SVP, head of biology at Nimbus. The appointment puts Loh in contact with wholly owned discovery-stage programs against targets including STING and ACLY. Nimbus is also working on drugs in partnership with Celgene and has partnered with Genentech on a target familiar to Loh from her time at Kymera, IRAK4. Genentech is responsible for that program.

Working in partnership with Schrödinger, the computational chemistry specialist that co-founded the biotech, Nimbus has validated those targets and other therapeutic avenues for Loh and her team of biologists to pursue. 

“The company’s suite of well-validated targets provides valuable opportunities to develop novel therapeutic agents,” Loh said in a statement.

Loh leaves Kymera two months after co-founder and Chief Scientific Officer Nello Mainolfi replaced Laurent Audoly as CEO. When Audoly left, Kymera said the former CEO had “decided to pursue new entrepreneurial opportunities.” Two months later, Audoly is yet to publicly take up a new position.

Suggested Articles

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19.

Thermo Fisher's third-quarter revenue topped $8.52 billion, a 36% increase over the $6.27 billion raised during the same period in 2019.